Cite
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
MLA
Martin, Miguel, et al. “Activity of Docetaxel, Carboplatin, and Doxorubicin in Patient-Derived Triple-Negative Breast Cancer Xenografts.” Scientific Reports, vol. 11, no. 1, Mar. 2021, pp. 1–12. EBSCOhost, https://doi.org/10.1038/s41598-021-85962-4.
APA
Martin, M., Ramos-Medina, R., Bernat, R., García-Saenz, J. A., del Monte-Millan, M., Alvarez, E., Cebollero, M., Moreno, F., Gonzalez-Haba, E., Bueno, O., Romero, P., Massarrah, T., Echavarria, I., Jerez, Y., Herrero, B., Gonzalez del Val, R., Lobato, N., Rincon, P., Palomero, M. I., & Marquez-Rodas, I. (2021). Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. Scientific Reports, 11(1), 1–12. https://doi.org/10.1038/s41598-021-85962-4
Chicago
Martin, Miguel, Rocio Ramos-Medina, Rebeca Bernat, Jose Angel García-Saenz, Maria del Monte-Millan, Enrique Alvarez, Maria Cebollero, et al. 2021. “Activity of Docetaxel, Carboplatin, and Doxorubicin in Patient-Derived Triple-Negative Breast Cancer Xenografts.” Scientific Reports 11 (1): 1–12. doi:10.1038/s41598-021-85962-4.